Showing 1941-1950 of 3440 results for "".
MOC Sparks Anger, Frustration in Physician Community
https://practicaldermatology.com/topics/practice-management/moc-sparks-anger-frustration-in-physician-community/20898/Anti-MOC advocates wonder why they cannot get a seat at the table to discuss changing the system.Know Your Pigmented Lesions
https://practicaldermatology.com/youngmd-connect/resident-resource-center/know-your-pigmented-lesions/23560/A diagnostic challenge and review of a rare melanocytic lesion.Business Advisor: Before/After Pictures Are Worth More Than Words to Aesthetic Practices
https://practicaldermatology.com/topics/general-topics/business-advisor-beforeafter-pictures-are-worth-more-than-words-to-aesthetic-practices/21887/High-quality before and after pictures are a necessity in today's competitive marketplace. Make an investment in equipment and in training yourself and your staff.Biosimilars: Generic Biologics or Something Much More Complex?
https://practicaldermatology.com/topics/practice-management/biosimilars-generic-biologics-or-something-much-more-complex/21013/The looming availability of biosimilar medications raises important clinical and regulatory questions.Recent Developments
https://practicaldermatology.com/columns/recent-developments/recent-developments/20594/Galderma's Future, Allergan's Bonti Buy, and Sebacia Clearance
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-galderma-s-future-allergan-s-bonti-buy-and-sebacia-clearance--xgheloga/18233/Nestle's Board says it has come to the conclusion that the future growth opportunities of Nestlé Skin Health lie increasingly outside the Group's strategic scope and expects a review of strategic options for Nestlé Skin Health to be complete by mid-2019. Allergan is acquiring Bonti for 195 million dLidocaine Shortage: Perspectives, Alternatives, and Pathways Forward
https://practicaldermatology.com/topics/practice-management/lidocaine-shortage-perspectives-alternatives-and-pathways-forward/23949/Supply chain issues, communication barriers, and regulatory inconsistencies cause problems for practitioners and patients.New Products and Devices
https://practicaldermatology.com/columns/new-products/new-products-and-devices/20567/New products and pharmacologic developmentsIn Focus: Psoriasis
https://practicaldermatology.com/topics/practice-management/in-focus-psoriasis/21311/In the Pipeline: New Approaches to Vitiligo, Congenital Ichthyosis, and More
https://practicaldermatology.com/topics/pigmentary-disorders/in-the-pipeline-new-approaches-to-vitiligo-congenital-ichthyosis-and-more/23714/Inflammatory diseases with few or no specific treatments may soon have approved interventions.